Fovista fails to demonstrate any benefit for wet AMD
In order to improve the outcomes of people being treated with eye injections for wet age-related macular degeneration (AMD), several companies are developing treatments to be used in conjunction with the existing treatments such as Lucentis (ranibizumab) and Eylea (aflibercept). The most advanced of these investigational products is Fovista (pegpleranib).
The 12-month results of two large phase 3 (registration) trials involving over 1250 patients with wet AMD have just been released and show that combining Fovista with Lucentis did not result in any additional improvement in vision compared to using Lucentis on its own.
These results are disappointing given that an earlier phase 2 trial showed positive results. It is now very unlikely that this treatment will move forward in its current form for treating wet AMD.
The manufacturer, Ophthotech, issued a press release on the results which can be found at their website.